Transaction #8424 · Form 4 · 0001437749-25-035182
Moleculin Biotech, Inc. · Stock award · Stock option (right to buy)
Moleculin Biotech, Inc. · Transacted November 12, 2025 · Filed November 14, 2025
What does this filing report?
An SEC Form 4 filing for Moleculin Biotech, Inc. records a stock award involving Stock option (right to buy) on November 12, 2025. The reported quantity was 830,000. The filing date is November 14, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Moleculin Biotech, Inc.
- Company CIK
- 0001659617
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 830,000
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 3,210,731
- Ownership description
- Not reported
- SEC acceptance time
- Nov 14, 2025, 4:07 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- KLEMP WALTER V ↗
CEO and President · Director
CIK 0000938419
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 830,000
- Conversion / exercise price
- 0.49
- Exercise date
- Not reported
- Expiration date
- November 12, 2035
Filing footnotes & remarks
- F1
- The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
- F2
- Issued in connection with the reporting person's employment with the Company.
- F3
- Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
- F4
- On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.